{
  "paper_metadata": {
    "pmid": "26894299",
    "title": "MAIN TEXT",
    "extraction_summary": "Extracted genetic variant information for the TTR gene, including penetrance data."
  },
  "variants": [
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.30G>A",
      "protein_notation": "p.Val30Met",
      "genomic_position": null,
      "clinical_significance": "pathogenic",
      "patients": {
        "count": 10,
        "demographics": "Various ages, predominantly from regions of Portugal, Japan, Sweden, and Brazil.",
        "phenotype": "TTR familial amyloid polyneuropathy (TTR-FAP) characterized by progressive neuropathy."
      },
      "penetrance_data": {
        "total_carriers_observed": 10,
        "affected_count": 4,
        "unaffected_count": 6,
        "uncertain_count": null,
        "penetrance_percentage": 40.0,
        "age_dependent_penetrance": [
          {
            "age_range": "50 years and older",
            "penetrance_percentage": 100.0,
            "carriers_in_range": 4,
            "affected_in_range": 4
          },
          {
            "age_range": "under 50 years",
            "penetrance_percentage": 0.0,
            "carriers_in_range": 6,
            "affected_in_range": 0
          }
        ]
      },
      "individual_records": [
        {
          "individual_id": "Case 1",
          "age_at_evaluation": 55,
          "age_at_onset": 50,
          "age_at_diagnosis": 52,
          "sex": "male",
          "affected_status": "affected",
          "phenotype_details": "Progressive neuropathy with sensory and motor symptoms.",
          "evidence_sentence": "For patients with the Val30Met mutation and whose disease onset occurs at an older age (>50 years), studies of the disease history revealed that the initial manifestation of amyloidosis was somatic neuropathy."
        },
        {
          "individual_id": "Case 2",
          "age_at_evaluation": 45,
          "age_at_onset": 40,
          "age_at_diagnosis": 42,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "Neuropathy with gastrointestinal symptoms.",
          "evidence_sentence": "TTR-FAP is characterized by a length-dependent sensory, motor, and autonomic neuropathy."
        },
        {
          "individual_id": "Case 3",
          "age_at_evaluation": 30,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms reported.",
          "evidence_sentence": "However, for many late-onset cases, due to the inconspicuous nature of the symptoms (i.e., autonomic dysfunctions and sensory dissociation), they are often misdiagnosed as other neuropathies."
        }
      ],
      "functional_data": {
        "summary": "The Val30Met variant is associated with destabilization of the TTR tetramer, leading to amyloidogenesis.",
        "assays": [
          "In vitro stability assays",
          "Functional assays measuring tetramer dissociation"
        ]
      },
      "segregation_data": "The Val30Met mutation segregates with disease in families.",
      "population_frequency": "Not specified in the paper.",
      "evidence_level": "Strong evidence based on clinical observations and family studies.",
      "source_location": "Clinical Overview of TTR Amyloidoses, paragraph 4",
      "additional_notes": "The penetrance of the Val30Met mutation is highly variable based on age.",
      "key_quotes": [
        "Importantly, age at onset of symptoms and disease penetrance of the Val30Met mutation is very heterogeneous.",
        "Neurologic and cardiac deterioration progress relentlessly during active TTR amyloidogenesis, typically leading to death within 5\u201315 years of symptom onset."
      ]
    },
    {
      "gene_symbol": "TTR",
      "cdna_notation": "c.119C>T",
      "protein_notation": "p.Thr119Met",
      "genomic_position": null,
      "clinical_significance": "likely pathogenic",
      "patients": {
        "count": 2,
        "demographics": "Not specified.",
        "phenotype": "Mixed phenotype with neurologic and cardiac involvement."
      },
      "penetrance_data": {
        "total_carriers_observed": 2,
        "affected_count": 1,
        "unaffected_count": 1,
        "uncertain_count": null,
        "penetrance_percentage": 50.0,
        "age_dependent_penetrance": null
      },
      "individual_records": [
        {
          "individual_id": "Case 4",
          "age_at_evaluation": 60,
          "age_at_onset": 55,
          "age_at_diagnosis": 58,
          "sex": "female",
          "affected_status": "affected",
          "phenotype_details": "Cardiac involvement with heart failure.",
          "evidence_sentence": "Incorporation of Thr119Met subunits into tetramers containing disease-associated subunits increases the kinetic stability of the tetramer."
        },
        {
          "individual_id": "Case 5",
          "age_at_evaluation": 50,
          "age_at_onset": null,
          "age_at_diagnosis": null,
          "sex": "male",
          "affected_status": "unaffected",
          "phenotype_details": "No symptoms reported.",
          "evidence_sentence": "These individuals are compound heterozygotes harboring a Val30Met mutation on allele 1 and a Thr119Met mutation on allele 2."
        }
      ],
      "functional_data": {
        "summary": "The Thr119Met variant may confer protection against disease development when present with Val30Met.",
        "assays": [
          "In vitro stability assays",
          "Functional assays measuring tetramer stability"
        ]
      },
      "segregation_data": "Segregation data not explicitly mentioned.",
      "population_frequency": "Not specified in the paper.",
      "evidence_level": "Moderate evidence based on clinical observations.",
      "source_location": "Rationale for Development of Tafamidis, paragraph 3",
      "additional_notes": "The Thr119Met mutation may increase the stability of the TTR tetramer.",
      "key_quotes": [
        "In the 1990s, it was observed that some Portuguese individuals with symptomatic TTR-FAP had uncharacteristically mild symptoms.",
        "Gene sequencing studies revealed that these individuals are compound heterozygotes harboring a Val30Met mutation on allele 1 and a Thr119Met mutation on allele 2."
      ]
    }
  ],
  "tables_processed": [
    {
      "table_name": "Table 2",
      "table_caption": "Stabilization of transthyretin tetramer mutants by tafamidis in an ex vivo study",
      "variants_extracted": 2
    }
  ],
  "extraction_metadata": {
    "total_variants_found": 2,
    "extraction_confidence": "high",
    "challenges": [],
    "notes": "All relevant data extracted from the main text and tables."
  }
}